Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 14/20 | 0.63 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29660853 | 0.85 | NLRP3 (0.50) | NLRP3F10SMN1; SMN2TSHRHTT | |
| SCHEMBL29030778 | 0.80 | NLRP3 (0.60) | NLRP3SMN1; SMN2 | |
| SCHEMBL29660985 | 0.78 | NLRP3 (0.62) | NLRP3P2RX3 | |
| SCHEMBL29660806 | 0.78 | NLRP3 (0.59) | NLRP3SMN1; SMN2TSHR | |
| SCHEMBL31305786 | 0.78 | NLRP3 (0.55) | NLRP3F10SMN1; SMN2TSHRHTT | |
| SCHEMBL24077258 | 0.78 | NLRP3 (0.53) | NLRP3P2RX3SMN1; SMN2TSHRHTT | |
| SCHEMBL31305701 | 0.76 | NLRP3 (0.50) | NLRP3SMN1; SMN2TSHRHTT | |
| SCHEMBL31305708 | 0.75 | NLRP3 (0.54) | NLRP3F10SMN1; SMN2TSHRHTT | |
| SCHEMBL29660890 | 0.75 | NLRP3 (0.75) | NLRP3P2RX3 | |
| SCHEMBL29660802 | 0.73 | NLRP3 (0.72) | NLRP3P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043450-A1 | NEW COMPOUND | JANSSEN PHARMACEUTICA NV (BE) | 2024-02-08 | — | — | US | disclosed |
| EP-4217347-A1 | NEW COMPOUNDS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| CN-116194445-A | New compounds | 詹森药业有限公司 | 2023-05-30 | — | — | CN | disclosed |
| WO-2022063896-A1 | NEW COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043450-A1 | NEW COMPOUND | NLRP3, NLRP1, PYCARD | NLRP3 1/4885P2RX3 42/4885F10 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.